Opportunity Information: Apply for RFA EB 13 002
Apply for RFA EB 13 002
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Development and Translation of Medical Technologies to Reduce Health Disparities (SBIR) (R43/R44)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.286 Discovery and Applied Research for Technological Innovations to Improve Human Health 93.307 Minority Health and Health Disparities Research.
- This funding opportunity was created on Feb 25, 2013 and posted on Feb 25, 2013.
- Applicants must submit their applications by Jan 7, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Small businesses.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH funding opportunity titled "Development and Translation of Medical Technologies to Reduce Health Disparities (SBIR) (R43/R44)" (Funding Opportunity Number: RFA EB 13 002) was a discretionary grant program designed to support small businesses developing practical medical technologies that can measurably reduce health disparities. The core idea of the announcement is not just to invent new tools, but to translate them into real-world use in communities where gaps in healthcare access and outcomes are well documented. Projects were expected to focus on technologies that are effective in practice, affordable for the settings and patients who need them, culturally acceptable to the populations being served, and realistically deliverable in the environments where disparity populations receive care.
This FOA used the Small Business Innovation Research (SBIR) mechanism, specifically the R43/R44 pathway, which aligns with the typical two-stage SBIR structure: Phase I (R43) for early feasibility and proof-of-concept work, followed by Phase II (R44) for further development, validation, and steps toward translation and implementation. A defining requirement of this particular opportunity was that responsive applications had to include a formal collaboration during both Phase I and Phase II with a healthcare provider or another healthcare organization that serves one or more health disparity populations. In other words, applicants needed more than an advisory letter or informal relationship; they needed an established partnership with an organization positioned to help ensure the technology is grounded in real clinical workflows, community needs, and practical constraints.
Eligibility was limited to small business concerns, consistent with SBIR rules, and the sponsoring agency was the National Institutes of Health (NIH). The announcement was categorized under health-related funding activities and connected to CFDA numbers 93.286 (Discovery and Applied Research for Technological Innovations to Improve Human Health) and 93.307 (Minority Health and Health Disparities Research). There was no cost sharing or matching requirement, which is typical for many NIH SBIR opportunities and reduces barriers for smaller companies that may not have large reserves of non-federal capital.
From an applicant strategy standpoint, this FOA strongly signaled that NIH was looking for technologies with a clear line of sight to use in disparity-affected settings, rather than solutions that only work in well-resourced environments. That could include tools that lower cost, simplify training requirements, improve accessibility in rural or under-resourced urban areas, better accommodate language or cultural needs, or otherwise address structural barriers that contribute to unequal outcomes. The collaboration requirement also implies NIH wanted early and continuous input from real delivery sites serving disparity populations, increasing the likelihood the end product would be acceptable, adoptable, and scalable in the intended communities.
Key timeline details reflect that this was an older, now-archived opportunity. It was posted and created on Feb 25, 2013, with an original and final closing date of Jan 7, 2014, and an archive date of Feb 7, 2014. For further details, the FOA pointed to the NIH grants page at http://grants.nih.gov/grants/guide/rfa_files/RFA-EB-13-002.html, and provided NIH Office of Extramural Research (OER) webmaster contact information for access or technical linking issues (FBOWebmaster@OD.NIH.GOV).
Frequently Asked Questions (FAQs)
What is the name of this NIH funding opportunity?
The funding opportunity is titled "Development and Translation of Medical Technologies to Reduce Health Disparities (SBIR) (R43/R44)."
What is the Funding Opportunity Number (FONO)?
The Funding Opportunity Number is RFA EB 13 002.
What agency offered this grant opportunity?
The sponsoring agency was the National Institutes of Health (NIH).
What type of program was this?
This was a discretionary grant program using the Small Business Innovation Research (SBIR) mechanism.
Which SBIR award mechanisms were used under this FOA?
This FOA used the R43/R44 pathway, which aligns with the SBIR two-stage structure: Phase I (R43) and Phase II (R44).
What was the main purpose of the opportunity?
The purpose was to support small businesses developing practical medical technologies that can measurably reduce health disparities, with a strong emphasis on translation into real-world use in communities where healthcare access and outcomes gaps are well documented.
Was this opportunity focused only on inventing new technologies?
No. The core idea was not just to invent new tools, but to translate them into real-world use in disparity-affected settings.
What kinds of projects were considered responsive to this FOA?
Projects were expected to focus on medical technologies that are effective in practice, affordable for the settings and patients who need them, culturally acceptable to the populations being served, and realistically deliverable in the environments where disparity populations receive care.
What did NIH signal about the kinds of settings these technologies should work in?
The FOA strongly signaled interest in technologies with a clear line of sight to use in disparity-affected settings, rather than solutions that only work in well-resourced environments.
What are examples of technology characteristics that align with the FOA's intent?
Examples described or implied by the FOA include tools that lower cost, simplify training requirements, improve accessibility in rural or under-resourced urban areas, better accommodate language or cultural needs, or address structural barriers that contribute to unequal outcomes.
Who was eligible to apply?
Eligibility was limited to small business concerns, consistent with SBIR rules.
Was a collaboration required as part of the application?
Yes. A defining requirement was that responsive applications had to include a formal collaboration during both Phase I and Phase II with a healthcare provider or another healthcare organization that serves one or more health disparity populations.
Does the collaboration requirement apply to both Phase I and Phase II?
Yes. The collaboration was required during both Phase I (R43) and Phase II (R44).
What type of partner organization was required for the collaboration?
The collaboration had to be with a healthcare provider or another healthcare organization that serves one or more health disparity populations.
Was an informal relationship or advisory letter enough to meet the collaboration requirement?
No. The FOA indicated applicants needed more than an advisory letter or informal relationship; they needed an established partnership with an organization positioned to help ensure the technology is grounded in real clinical workflows, community needs, and practical constraints.
Why did NIH include a formal collaboration requirement?
Based on the FOA description, the collaboration requirement implied NIH wanted early and continuous input from real delivery sites serving disparity populations to increase the likelihood the end product would be acceptable, adoptable, and scalable in the intended communities.
Was cost sharing or matching required?
No. There was no cost sharing or matching requirement.
What funding activity area did this opportunity fall under?
The announcement was categorized under health-related funding activities.
Which CFDA numbers were associated with this opportunity?
This opportunity was connected to CFDA 93.286 (Discovery and Applied Research for Technological Innovations to Improve Human Health) and CFDA 93.307 (Minority Health and Health Disparities Research).
When was this FOA posted and created?
It was posted and created on February 25, 2013.
What was the closing date for applications?
The original and final closing date was January 7, 2014.
Is this funding opportunity still open?
No. This was an older, now-archived opportunity.
When was the opportunity archived?
The archive date was February 7, 2014.
Where can someone find the FOA details online?
The FOA pointed to the NIH grants page at http://grants.nih.gov/grants/guide/rfa_files/RFA-EB-13-002.html.
Who should be contacted for access or technical linking issues related to the FOA?
The FOA provided the NIH Office of Extramural Research (OER) webmaster contact for access or technical linking issues: FBOWebmaster@OD.NIH.GOV.
Browse more opportunities from the same category: Health
Next opportunity: 2013 Fish Passage Inspection Coordination Program
Previous opportunity: Comprehensive HIV Prevention, Care and Treatment for the National Defense Force of Ethiopia (NDFE) under the Presidents Emergency Plan for AIDS Relief (PEPFAR)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA EB 13 002
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA EB 13 002) also looked into and applied for these:
| Funding Opportunity |
|---|
| Strategic Assessments for Strategic Action (SASA) in India under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH13 1361 Funding Number: CDC RFA GH13 1361 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
| Technical Assistance to National AIDS Control Program (NACP) in India for Strategic Planning and Decision Making under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH13 1362 Funding Number: CDC RFA GH13 1362 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $500,000 |
| Establishment of a Strategic Partnership to Strengthen the South African National AIDS Council under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH13 1338 Funding Number: CDC RFA GH13 1338 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $2,000,000 |
| Partnerships for Biodefense (R01) Apply for RFA AI 13 013 Funding Number: RFA AI 13 013 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| Strengthening the South African National Department of Health (NDOH) to implement and evaluate evidence based public health program, surveillance and disease control efforts under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH13 1337 Funding Number: CDC RFA GH13 1337 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $10,000,000 |
| Strengthening strategic information, program implementation and capacity building in order to reduce morbidity and mortality in the Republic of South Africa under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH13 1340 Funding Number: CDC RFA GH13 1340 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $10,000,000 |
| Strengthen capacity of the South African Governments Department of Health to provide quality and sustainable clinical care for HIV infected patients with complicated HIV and HIV/TB treatment management, including 2nd and 3rd line and other antiretrov Apply for CDC RFA GH13 1335 Funding Number: CDC RFA GH13 1335 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $5,000,000 |
| Comprehensive HIV TB Prevention, Care and Treatment Services and Systems Strengthening, In Facilities of South Africas Department of Correctional Services (DCS) under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH13 1336 Funding Number: CDC RFA GH13 1336 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $12,000,000 |
| Building Capacity of the Vietnam Health System through Provision of HIV/AIDS Clinical Care Mentorship and Technical Assistance under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH13 1363 Funding Number: CDC RFA GH13 1363 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,500,000 |
| Sustaining Influenza Surveillance Networks and Response to Seasonal and Pandemic Influenza by National Health Authorities outside the United States Apply for CDC RFA IP13 1304 Funding Number: CDC RFA IP13 1304 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $500,000 |
| Service Area Competition Additional Area (SAC AA) Baxley, GA and Brooklyn, NY Apply for HRSA 13 271 Funding Number: HRSA 13 271 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Support and Implement Behavioral Change Communication to Increase Uptake of Highly Effective Prevention Services and Behaviors in Selected Urban and Rural Populations in the Southern and Western Provinces of the Republic of Zambia under the President Apply for CDC RFA GH13 1351 Funding Number: CDC RFA GH13 1351 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,500,000 |
| NINDS Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral Fellows in MD PhD Programs (F31) Apply for PAR 13 127 Funding Number: PAR 13 127 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Increase Access to Comprehensive HIV/AIDS Prevention Care and Treatment Services in the Democratic Republic of Congo under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH13 1321 Funding Number: CDC RFA GH13 1321 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $12,000,000 |
| Provision of Comprehensive Care and Treatment Programs by Local Indigenous Entities in the United Republic of Tanzania under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH13 1322 Funding Number: CDC RFA GH13 1322 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $10,000,000 |
| Strengthening Human Resources for Health through Public Health Training Improvements at the Muhimbili University of Health and Allied Sciences (MUHAS), School of Public Health and Social Sciences (SPHSS) in the United Republic of Tanzania under PEPFA Apply for CDC RFA GH13 1323 Funding Number: CDC RFA GH13 1323 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,500,000 |
| Technical Assistance for Strengthening of Blood Transfusion Services and Increasing Access to Safe Blood in India under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH13 1360 Funding Number: CDC RFA GH13 1360 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $2,000,000 |
| Supporting the implementation and capacity building of HIV/AIDS prevention interventions for youth using evidence based approaches in South Africa under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH13 1341 Funding Number: CDC RFA GH13 1341 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $6,000,000 |
| Accelerating Progress Against TB in Kenya (APA K) Apply for RFA 615 13 000003 Funding Number: RFA 615 13 000003 Agency: Kenya USAID Nairobi Category: Health Funding Amount: $40,000,000 |
| Genomes to Natural Products (U01) Apply for RFA GM 14 002 Funding Number: RFA GM 14 002 Agency: National Institutes of Health Category: Health Funding Amount: $2,250,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA EB 13 002", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.